Persistent pulmonary hypertension of the newborn (PPHN), is defined as a failure of the pulmonary vasculature to relax at birth and consequently of the normal adaptation to extra uterine life of the fetal heart/lung system, resulting in hypoxemia. This condition, occurs in about 1-2 newborns per 1000 live births and despite significant improvements in treatment it is associated with substantial infant mortality and morbidity. Over the years wider application of inhaled nitric oxide (iNO) therapy and improved ventilation strategies including surfactant, high-frequency oscillatory ventilation has led to a decrease in the need for invasive life-sustaining therapies such as extracorporeal membrane oxygenation (ECMO). Mortality rate varies from 10 to 20 % of affected newborns in developed countries, but it is much higher when PPHN is refractory to the above reported therapies or when they are not available. As a consequence, development of new therapeutic strategies for severe PPHN is crucial. In particular, recent studies seem to show that sildenafil, a phosphodiesterase inhibitor type 5 that selectively reduces pulmonary vascular resistance may be a useful therapeutic adjunct to critically ill neonates with PPHN.
Keywords: Pulmonary hypertension of the newborn, Bronchopulmonary dysplasia, inhaled nitric oxide
Vasopeptidase Inhibition for Blood Pressure Control: Emerging Experience
Current Pharmaceutical Design Pre-eclampsia Versus Cardiovascular Disease Versus CRP
Current Hypertension Reviews Models to Study Atherosclerosis: A Mechanistic Insight
Current Vascular Pharmacology Does HbA1cc Play a Role in the Development of Cardiovascular Diseases?
Current Pharmaceutical Design Smoking and Hypertension: Effects on Clinical, Biochemical and Pathological Variables Due to Isolated or Combined Action on Cardiovascular System
Current Pharmaceutical Design Natriuretic Peptide Testing in Primary Care
Current Cardiology Reviews Novel Therapeutic Targets for Phosphodiesterase 5 Inhibitors: current state-of-the-art on systemic arterial hypertension and atherosclerosis
Current Pharmaceutical Biotechnology Diabetes in Racial and Ethnic Minorities in the United States: Individualizing Approaches to Diagnosis and Management
Current Diabetes Reviews Role of Angiotensin-1-Receptor Blockers In Cardiorenal Disease
Current Drug Therapy Impact of Angiotensin Converting Enzyme Inhibitors/Angiotensin Receptors Blockers on Mortality in Acute Heart Failure Patients with Left Ventricular Systolic Dysfunction in the Middle East: Observations from the Gulf Acute Heart Failure Registry (Gulf CARE)
Current Vascular Pharmacology Ultrasonographic Assessment of Cirrhosis and Portal Hypertension
Current Medical Imaging Pharmacology of L-type Calcium Channels: Novel Drugs for Old Targets?
Current Molecular Pharmacology Review of Olmesartan Medoxomil in Achieving Guideline-Recommended Target BP Goals and Implications for Managed Care
Current Hypertension Reviews The Role of Anticoagulation in IPF
Current Respiratory Medicine Reviews Nocturnal Hypertension and Chronic Kidney Disease
Current Hypertension Reviews Recent Patents on Biomedical Applications for the Treatment of Atherosclerosis
Recent Patents on Regenerative Medicine (Discontinued) Renin-Angiotensin Antagonists: Therapeutic Effects Beyond Blood Pressure Control?
Current Pharmaceutical Design The Reno-Protective Effect of the Dual Blockade of the Renin Angiotensin System (RAS)
Current Pharmaceutical Design Role of Nitrosative Stress and Peroxynitrite in the Pathogenesis of Diabetic Complications. Emerging New Therapeutical Strategies
Current Medicinal Chemistry Combination of Thiazide Diuretics and Angiotensin Receptor Blockers Attenuates Osteoporosis in Hypertensive Rats
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Under Re-organization)